drugset / Trial / NCT02572817

Comparing the Efficacy and Safety of High-Titer Versus Low-Titer Anti-Influenza Immune Plasma for the Treatment of Severe Influenza A

NCT02572817 ↗

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study assessed the efficacy and safety of anti-influenza immune plasma, as an addition to standard of care antivirals, in participants hospitalized with severe influenza A infection.

Timeline

Start
2015-11
Primary completion
2018-04-26
Completion
2018-05-18

Outcome

Missed primary endpoint

registry p = 0.54; Odds Ratio (OR) 1.22 (95% CI 0.65 to 2.29) NCT02572817 ↗

paper The proportional OR for improved clinical status on day 7 was 1·22 (95% CI 0·65-2·29, p=0·54). PMID 31582360 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject High-titer anti-influenza plasma Unknown 225 ml Intravenous
Subject High-titer anti-influenza plasma Unknown 350 ml Intravenous
Comparator Low-titer anti-influenza plasma Unknown 225 ml Intravenous
Comparator Low-titer anti-influenza plasma Unknown 350 ml Intravenous

Indications